A bifunctional platinum(II) antitumor agent that forms DNA adducts with affinity for the estrogen receptor
Name
Essigmann_Bifunctional platinum.pdf
Size
1.16 MB
Format
Adobe PDF
Checksum (MD5)
11f567b65a6e0157570038c9d226e6b4
Author(s)
Kim, Eunsuk
Rye, Peter T.
Essigmann, John M.
Croy, Robert G.
Date Issued
October 2008
Journal
Journal of Inorganic Biochemistry
Publisher
Elsevier
Citation
Kim, Eunsuk, Peter T. Rye, John M. Essigmann, and Robert G. Croy. “A Bifunctional platinum(II) Antitumor Agent That Forms DNA Adducts with Affinity for the Estrogen Receptor.” Journal of Inorganic Biochemistry 103, no. 2 (February 2009): 256–261.
Version
Author's final manuscript
Abstract
A strategy is described for the re-design of DNA damaging platinum(II) complexes to afford elevated toxicity towards cancer cells expressing the estrogen receptor (ER). Two platinum-based toxicants are described in which a DNA damaging warhead, [Pt(en)Cl[subscript 2]] (en, ethylenediamine), is tethered to either of two functional groups. The first agent, [6-(2-amino-ethylamino)-hexyl]-carbamic acid 2-[6-(7α-estra-1,3,5,(10)-triene)-hexylamino]-ethyl ester platinum(II) dichloride ((Est-en)PtCl[subscript 2]), terminates in a ligand for the ER. The second agent is a control compound lacking the steroid; this compound, N-[6-(2-amino-ethylamino)-hexyl]-benzamide platinum(II) dichloride ((Bz-en)PtCl[subscript 2])), terminates in a benzamide moiety, which lacks affinity for the ER. Using a competitive binding assay, Est-en had 28% relative binding affinity (RBA) for the ER as compared to 17β-estradiol. After covalent binding to a synthetic DNA duplex 16-mer, the compound retained its affinity for the ER; specificity of the binding event was demonstrated by the ability of free 17β-estradiol as a competitor to disrupt the DNA adduct-ER complex. The (Est-en)PtCl[subscript 2] compound showed higher toxicity against the ER positive ovarian cancer cell line CAOV3 than did the control compound. (Est-en)PtCl[subscript 2] was also more toxic to the ER positive breast cancer line, MCF-7, than to an ER negative line, MDA-MB231.
MIT Department
Massachusetts Institute of Technology. Center for Environmental Health Sciences
Massachusetts Institute of Technology. Department of Biological Engineering
Massachusetts Institute of Technology. Department of Chemistry
Terms of Use
Creative Commons Attribution-Noncommercial-NoDerivatives
Persistent DSpace Link
DOI of Published Version
https://doi.org/10.1016/j.jinorgbio.2008.10.013
